{"DataElement":{"publicId":"7149708","version":"2","preferredName":"Disease Progression Or Disease Transformation Difference Myelodysplastic Syndrome Or Acute Myeloid Leukemia Subtype Classification Type","preferredDefinition":"A description of the different myelodysplastic syndrome or acute myeloid leukemia subtype after disease progression or disease transformation.","longName":"7149802v1.00:7203661v1.10","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7149802","version":"1","preferredName":"Disease Progression Or Disease Transformation Difference Myelodysplastic Syndrome Or Acute Myeloid Leukemia Subtype","preferredDefinition":"The worsening of a disease over time._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state._The quality of being unlike or dissimilar._A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A group forming a type within a larger type.","longName":"7204253v1.0:7161764v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7204253","version":"1","preferredName":"Disease Progression Or Disease Transformation Difference","preferredDefinition":"The worsening of a disease over time.:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.:The quality of being unlike or dissimilar.","longName":"C17747:C37998:C123583:C46003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Transformation","conceptCode":"C123583","definition":"A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Difference","conceptCode":"C46003","definition":"The quality of being unlike or dissimilar.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0FBC2DC-01D9-4832-E053-F662850AB482","latestVersionIndicator":"Yes","beginDate":"2020-03-16","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-03-16","modifiedBy":"ONEDATA","dateModified":"2020-03-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7161764","version":"1","preferredName":"Myelodysplastic Syndrome Or Acute Myeloid Leukemia Subtype","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:A group forming a type within a larger type.","longName":"C3247:C37998:C3171:C25696","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DD91885-B9DC-76C3-E053-F662850A7DF2","latestVersionIndicator":"Yes","beginDate":"2020-02-05","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-02-05","modifiedBy":"ONEDATA","dateModified":"2020-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9CEB7D51-3D3C-0245-E053-F662850A8DA5","latestVersionIndicator":"Yes","beginDate":"2020-01-24","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-01-24","modifiedBy":"MALUMK","dateModified":"2020-12-03","changeDescription":"Released. 12/03/2020 KMM; Released. 11/11/2020 KMM; .Updated DEC with \"disease transformation\". 03/16/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7203661","version":"1.1","preferredName":"Myelodysplastic Syndrome Or Acute Myeloid Leukemia Classification Type","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Something distinguishable as an identifiable class based on common qualities.","longName":"7203661v1.10","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Myelodysplastic syndrome with low blasts and isolated 5q deletion (MDS-5q)","valueDescription":null,"ValueMeaning":{"publicId":"2738446","version":"1","preferredName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","longName":"2738446","preferredDefinition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with normal to increased, often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with del(5q)","conceptCode":"C6867","definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED8B-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60C6-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with low blasts and SF3B1 mutation (MDS-SF3B1)","valueDescription":null,"ValueMeaning":{"publicId":"14679043","version":"1","preferredName":"Myelodysplastic Syndrome with Mutated SF3B1","longName":"14679043v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by mutation of SF3B1 gene. There is bone marrow dysplasia typically in one or more hematopoietic cell lineages. There are less than 5% blasts in bone marrow and less than 2% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Mutated SF3B1","conceptCode":"C198587","definition":"Myelodysplastic syndrome characterized by mutation of SF3B1 gene. There is bone marrow dysplasia typically in one or more hematopoietic cell lineages. There are less than 5% blasts in bone marrow and less than 2% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A32-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60C7-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with low blasts and ring sideroblasts","valueDescription":null,"ValueMeaning":{"publicId":"14468370","version":"1","preferredName":"Myelodysplastic Syndrome, Not Otherwise Specified","longName":"14468370v1.00","preferredDefinition":"Myelodysplastic syndrome with low blasts characterized by the absence of defining genetic abnormalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Not Otherwise Specified","conceptCode":"C198589","definition":"Myelodysplastic syndrome with low blasts characterized by the absence of defining genetic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04CD2441-C894-4544-E063-731AD00AC08A","latestVersionIndicator":"Yes","beginDate":"2023-09-07","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-09-07","modifiedBy":"DWARZEL","dateModified":"2023-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60C8-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with biallelic TP53 inactivation (MDS-biTP53)","valueDescription":null,"ValueMeaning":{"publicId":"14679044","version":"1","preferredName":"Myelodysplastic Syndrome with Biallelic TP53 Inactivation","longName":"14679044v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of biallelic TP53 inactivating alterations. They include biallelic TP53 gene mutations or one TP53 gene mutation and concurrent copy loss of TP53. There are less than 20% blasts in bone marrow and peripheral blood. It is associated with a poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Biallelic TP53 Inactivation","conceptCode":"C200376","definition":"Myelodysplastic syndrome characterized by the presence of biallelic TP53 inactivating alterations. They include biallelic TP53 gene mutations or one TP53 gene mutation and concurrent copy loss of TP53. There are less than 20% blasts in bone marrow and peripheral blood. It is associated with a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A33-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60C9-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with low blasts (MDS-LB; <5% BM, <2%PB)","valueDescription":null,"ValueMeaning":{"publicId":"14679045","version":"1","preferredName":"Myelodysplastic Syndrome with Low Blasts","longName":"14679045v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of less than 5% blasts in bone marrow and less than 2% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Low Blasts","conceptCode":"C200389","definition":"Myelodysplastic syndrome characterized by the presence of less than 5% blasts in bone marrow and less than 2% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A34-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60CA-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome, hypoplastic (MDS-h) <=25% cellularity by age","valueDescription":null,"ValueMeaning":{"publicId":"14679046","version":"1","preferredName":"Hypoplastic Myelodysplastic Syndrome","longName":"14679046v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by decreased cellularity in the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypoplastic Myelodysplastic Syndrome","conceptCode":"C122686","definition":"Myelodysplastic syndrome characterized by decreased cellularity in the bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A35-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60CB-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with increased blasts (MDS-IB1)","valueDescription":null,"ValueMeaning":{"publicId":"2838712","version":"1","preferredName":"Myelodysplastic Syndrome with Excess Blasts","longName":"2838712v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C7506","definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9753-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60CC-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with increased blasts (MDS-IB2)","valueDescription":null,"ValueMeaning":{"publicId":"2582030","version":"1","preferredName":"RAEB-2","longName":"2582030","preferredDefinition":"A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood. Approximately 33% of cases progress to acute leukemia.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","conceptCode":"C7168","definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Refreshed concept association to pick up correct symbol instead of  <. 12.15.17 Updated definition to match current NCIt as requested by NMDP. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60CD-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with fibrosis (MDS-f)","valueDescription":null,"ValueMeaning":{"publicId":"14679047","version":"1","preferredName":"Myelodysplastic Syndrome with Excess Blasts and Fibrosis","longName":"14679047v1.00","preferredDefinition":"Myelodysplastic syndrome with excess blasts associated with significant reticulin fibrosis of the bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts and Fibrosis","conceptCode":"C82595","definition":"Myelodysplastic syndrome with excess blasts associated with significant reticulin fibrosis of the bone marrow.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A36-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60CE-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Childhood MDS with low blasts, hypocellular","valueDescription":null,"ValueMeaning":{"publicId":"14679048","version":"1","preferredName":"Childhood Myelodysplastic Syndrome with Low Blasts, Hypocellular","longName":"14679048v1.00","preferredDefinition":"Childhood myelodysplastic syndrome with low blasts that is characterized by bone marrow hypocellularity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Myelodysplastic Syndrome with Low Blasts, Hypocellular","conceptCode":"C200397","definition":"Childhood myelodysplastic syndrome with low blasts that is characterized by bone marrow hypocellularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A37-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60CF-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Childhood MDS with low blasts, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"14679050","version":"1","preferredName":"Childhood Myelodysplastic Syndrome with Low Blasts, Not Otherwise Specified","longName":"14679050v1.00","preferredDefinition":"Childhood myelodysplastic syndrome with low blasts in which further characterization is not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Myelodysplastic Syndrome with Low Blasts, Not Otherwise Specified","conceptCode":"C200398","definition":"Childhood myelodysplastic syndrome with low blasts in which further characterization is not available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A39-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D0-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Childhood MDS with increased blasts","valueDescription":null,"ValueMeaning":{"publicId":"14679049","version":"1","preferredName":"Childhood Myelodysplastic Syndrome with Excess Blasts","longName":"14679049v1.00","preferredDefinition":"Myelodysplastic syndrome with excess blasts that occurs during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C188449","definition":"Myelodysplastic syndrome with excess blasts that occurs during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A38-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D1-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Chronic myelomonocytic leukemia (CMML), Myelodysplastic","valueDescription":null,"ValueMeaning":{"publicId":"14679051","version":"1","preferredName":"Myelodysplastic Chronic Myelomonocytic Leukemia","longName":"14679051v1.00","preferredDefinition":"Chronic myelomonocytic leukemia characterized by the absence of a markedly elevated white blood cell count in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Chronic Myelomonocytic Leukemia","conceptCode":"C203443","definition":"Chronic myelomonocytic leukemia characterized by the absence of a markedly elevated white blood cell count in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A3A-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D2-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Chronic myelomonocytic leukemia (CMML), Myeloproliferative","valueDescription":null,"ValueMeaning":{"publicId":"14679052","version":"1","preferredName":"Myeloproliferative Chronic Myelomonocytic Leukemia","longName":"14679052v1.00","preferredDefinition":"Chronic myelomonocytic leukemia characterized by the presence of a markedly elevated white blood cell count in the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Chronic Myelomonocytic Leukemia","conceptCode":"C203444","definition":"Chronic myelomonocytic leukemia characterized by the presence of a markedly elevated white blood cell count in the peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A3B-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D3-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic/myeloproliferative neoplasm with neutrophilia","valueDescription":null,"ValueMeaning":{"publicId":"2837831","version":"1","preferredName":"Atypical Chronic Myeloid Leukemia","longName":"2837831","preferredDefinition":"A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-481E-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D4-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis (MDS / MPN–RS–T)","valueDescription":null,"ValueMeaning":{"publicId":"14679053","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and Thrombocytosis","longName":"14679053v1.00","preferredDefinition":"A myelodysplastic/myeloproliferative neoplasm characterized by thrombocytosis, anemia, blasts less than 5% in bone marrow and less than 1% in peripheral blood, presence of SF3B1 gene mutation, absence of BCR/ABL fusion, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm with SF3B1 Mutation and Thrombocytosis","conceptCode":"C198581","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by thrombocytosis, anemia, blasts less than 5% in bone marrow and less than 1% in peripheral blood, presence of SF3B1 gene mutation, absence of BCR/ABL fusion, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F14BB3B-5A3C-2638-E063-731AD00A4FC5","latestVersionIndicator":"Yes","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D5-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"MDS/MPN with ring sideroblasts (>=15% ring sideroblasts and wild type SF3B1) and thrombocytosis","valueDescription":null,"ValueMeaning":{"publicId":"6037337","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis","longName":"6037337","preferredDefinition":"A myelodysplastic/myeloproliferative neoplasm with morphologic and clinical characteristics of refractory anemia with ring sideroblasts, marked thrombocytosis, and abnormal megakaryocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","conceptCode":"C82616","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by marked thrombocytosis, anemia, erythroid lineage dysplasia, presence or absence of multilineage dysplasia, 15% or more ring sideroblasts, blasts less than 5% in bone marrow and less than 1% in peripheral blood, absence of BCR/ABL fusion, absence of SF3B1 mutation, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4EAB-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D6-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-02-13","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome / myeloproliferative neoplasm, not otherwise specified","valueDescription":null,"ValueMeaning":{"publicId":"4130276","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","longName":"4130276","preferredDefinition":"This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a myeloproliferative neoplasm, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative neoplasm category.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","conceptCode":"C27780","definition":"A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18569AC-00DE-4E6D-E040-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F16E440-60D7-2801-E063-731AD00A620A","beginDate":"2024-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7203660","version":"1","preferredName":"Myelodysplastic Syndrome Or Acute Myeloid Leukemia Classification Type","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Something distinguishable as an identifiable class based on common qualities.","longName":"7203660v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0ACD8A1-9FF3-5FAA-E053-F662850A96BA","latestVersionIndicator":"Yes","beginDate":"2020-03-12","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-03-12","modifiedBy":"ONEDATA","dateModified":"2020-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F169589-07B9-0E85-E063-731AD00AC0AC","latestVersionIndicator":"Yes","beginDate":"2020-03-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-02-13","changeDescription":".Released 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_MDS_mds_aml_pst_trans_ty","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the MDS subtype or AML after transformation","type":"Application Standard Question Text","description":"Specify the MDS subtype or AML after transformation","url":null,"context":"NHLBI"},{"name":"PQT","type":"Preferred Question Text","description":"What was the different myelodysplastic syndrome or acute myeloid leukemia subtype after disease progression or disease transformation?","url":null,"context":"NHLBI"},{"name":"Specify the MDS subtype or AML after transformation","type":"Alternate Question Text","description":"Specify the MDS subtype or AML after transformation","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F174A85-96DB-3CBB-E063-731AD00A9C7B","latestVersionIndicator":"Yes","beginDate":"2020-01-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":"Released. 11/11/2020 KMM; System generated def displayed as alt def. 01/24/2020 KMM. System generated def displayed as alt def. 01/24/2020 KMM. System generated def displayed as alt def. 03/16/2020 KMM","administrativeNotes":"2024.1.16 Created per ticket request CADSR0003263. ak","unresolvedIssues":null,"deletedIndicator":"No"}}